Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study

Annals of Hematology

Volumn 91, Issue 6, 2012, Pages 931-939

  Rigacci, L ^a   Puccini, B ^b   Dodero, A ^b   Iacopino, P ^b   Castagna, L ^b   Bramanti, S ^b   Ciceri, F ^b   Fanin, R ^b   Rambaldi, A ^b   Falda, M ^b   Milone, G ^b   Guidi, S ^b   Martelli, M F ^b   Mazza, P ^b   Oneto, R ^b   Bosi, A ^b   Foa R ^b   Leoni, P ^b   Liso, V ^b   Pioltelli, P ^b   Cascavilla, N ^b   Scime R ^b   Rizzoli, V ^b   Ballestrero, A ^b   Raimondi, R ^b   Arcese, W ^b   Musso, M ^b   Benedetti, F ^b   Guerrasio, A ^b   Majolino, I ^b   Lambertenghi, D G ^b   Baccarani, M ^b   Bacigalupo, A ^b   Petrini, M ^b   Carella, A M ^b   Levis, A ^b   La Nasa, G ^b   Merli, F ^b   Narni, F ^b   Lauria, F ^b   Cortelazzo, S ^b   Longinotti, M ^b   Olivieri, A ^b   Favre, C ^b   Cantore, N ^b   Da Prada, G A ^b   Selleri, C ^b   Bruno, B ^b   Giovanni, M ^b   Leone, G ^b   Di Bartolomeo, P ^b   Morandi, S ^b   Vallisa, D ^b   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NONE

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Diffuse largeBcelllymphoma; Graft versus lymphoma; Reduced intensity conditioning regimen; Salvage therapy

Indexed keywords

ANTIBODY; BUSULFAN; CD52 ANTIBODY; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DATA BASE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DATABASES, FACTUAL; FEMALE; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITALY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84862701403     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1395-9     Document Type: Article

References (47)

1. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, Somers R, Rizzoli V, Harousseau JL, Sotto JJ, Cahn JY, Gullhot F, Biggs J, Sonneveld P, Misset JL, Manna A, Jagannath S, Guglielmi C, Chevreau C, Delmer A, Santini G, Coiffier B (1991) Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77(7):1587-1592
2. Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, Botto B, Ciccone G, Gaidano G, Falchi L, Freilone R, Novero D, Orsucci L, Pavone V, Pogliani E, Rota-Scalabrini D, Salvi F, Tonso A, Tucci A, Levis A (2009) Dose-dense and highdose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Hematologica 94(9):1250-1258
3. Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Recher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C (2009) Rituximab versus observation after high dose consolidative first-line chemotherapy with autologous stem cell transplantation in patients with poor risk diffuse large-B cell lymphoma. Ann Oncol 20(12):1985-1992
4. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Prappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142-2148, 15
5. Vanderbenghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH (1997) Role of a second transplant in the management of poor prognosis lymphomas: a report from the European Blood and Marrow Registry. J Clin Oncol 15:1595-1600 (Pubitemid 27167398)
6. de Lima M, van Besien KV, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE (1997) Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone marrow transplant 19:121-127 (Pubitemid 27068247)
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graftversus-leukemia reactions after bone marrow transplantation. Blood 75:555-562 (Pubitemid 20069191)
8. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN (1993) Gene-marking to trace origin or relapse after autologous bone marrow transplantation. Lancet 341:85-86 (Pubitemid 23028118)
9. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P (1992) Autologous versus allogeneic bone marrow transplantation for non Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:1690-1695 (Pubitemid 23059945)
10. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653
11. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non Hodgkin's lymphoma. Blood 84:1050-1055 (Pubitemid 24245868)
12. Schimmer AD, Jamal S, Messner H, Keating A, Maharchand J, Huebsch L, Walker I, Benger A, Gluck S, Smith A (2000) Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network. Bone Marrow Transplant 26:859-864
13. Toze CL, Shepherd JD, Connors JM, Voss NJ, Gascoyne RD, Hogge DE, Klingemann HG, Nantel SH, Nevill TJ, Philips GL, Reece DE, Sutherland HJ, Barnett MJ (2000) Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 25:605-612 (Pubitemid 30156585)
14. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR (2000) Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 6:272-279
15. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM (1998) Allogeneic bone marrow transplantation for low grade lymphoma. Blood 92:1832-1836 (Pubitemid 28406891)
16. Peggs KS, Mackinnon S, David L (2004) The role of allogeneic transplantation in non-Hodgkin's lymphoma. British Journal of Hematology 128:153-168
17. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood 91:756-763 (Pubitemid 28078275)
18. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 25:1021-1028
19. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease and treatment-related mortality. Blood 98:3595-3599
20. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP, Buzyn A, Boogaerts MA, Luan JJ, Maury S, Milpied NJ, Jouet JP, Ossenkoppele GJ, Sureda A (2011) Allogeneic stemcell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation registry. J Clin Oncol 10(29):1342-1348
21. SPSS Inc.SPSS for Windows, version 12. 0 Chicago: SPSS Inc. 1998
22. NCSS97 Number Cruncher Statistical System, Kaysville, UT, USA
23. Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L, Polliack A, Naparstek E (2003) Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 31:565-569 (Pubitemid 36546834)
24. Schouten HC, Armitage JO, Klassen LW, Vaughan WP, Bierman PJ, Weisenburger D, Kessinger A (1989) Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. Bone Marrow Transplant 4:119-121 (Pubitemid 19064918)
25. Tsai T, Goodman S, Saez R, Schiller G, Adkins D, Callander N, Wolff S, Freytes CO (1997) Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 20:859-863 (Pubitemid 27493924)
26. Bierman P (2000) Allogeneic bone marrow transplantation for lymphoma. Blood Rev 14(1):1-13 (Pubitemid 30216165)
27. Shah AJ, Kapoor N, Weinberg KI, Crooks GM, Kohn DB, Lenarsky C, Kaufman F, Epport K, Wilson K, Parkman R (2002) Second hematopoietic stem cell transplantation in pediatric patients: overall survival and long-term follow-up. Biol Blood Marrow Transplant 8:221-228 (Pubitemid 34520537)
28. Chiang KY, Weisdorf DJ, Davies SM, Enright H, Kersey JH, McGlave PB, Miller W, Ramsay NK, Steinbuch M, Wagner JE, Blazar BR (1996) Outcome of second bone marrow transplantation following uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant 17:39-42 (Pubitemid 26031888)
29. Horowitz MM, Bortin MM (1990) Current status of allogeneic bone marrow transplantation. Clin Transpl. 41-52
30. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Chakmplin RR (1996) Allogeneic bone marrow transplantation for poor prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 100:299-307 (Pubitemid 26111627)
31. Blau I, Basara N, Bischoff M, Gunzelmann S, Romer E, Kirsten D, Schmetzer B, Kiehl MG, Fauser AA (2000) Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 25:41-45 (Pubitemid 30093154)
32. Giralt S, Estey E, Albitar M, Van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andresson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 85:4531-4538
33. Kottanidis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsch JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graftversus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425
34. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russel N, de Elvira CR, Taghipour G, Schmitz N (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the lymphoma working party of the European group for blood and bone marrow transplantation. Blood 100:4310-4316 (Pubitemid 35429668)
35. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF (2004) Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419-2423 (Pubitemid 41115399)
36. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scime R, Narni F, Pogliani E, Locasciulli A, Dilani R, Carniti C, Bacigalupo A, Rambaldi A, Bonifazi F, Olivieri A, Gianni AM, Tarella C (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pretransplant disease status and histotype heavily influence outcome. Leukemia 21:2361-2323
37. Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russel NK (2004) BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative disease: GVHD, toxicity and survival in 65 patients. Blood 103:428-434 (Pubitemid 38140069)
38. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR (2005) Efficacy of reduced intensity allogeneic stem cell transplantation in chemotherapy refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11:593-599 (Pubitemid 41001634)
39. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25:1021-1028 (Pubitemid 30303589)
40. Corradini P, Dodero A, Zallio F, Carcciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C (2004) Graft versus lymphoma effect in relapsed peripheral T-cell non Hodgkin's lymphomas after reduced-intensity conditioning followed allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176 (Pubitemid 41095152)
41. Kusumi E, Karni M, Kanda Y, Murashige N, Kishi Y, Suzuki R, Takeuchi K, Tanimoto TE, Mori T, Muta K, Tamaki T, Tanaka Y, Ogawa H, Yamane T, Taniguchi S, Takaue Y (2005) Reducedintensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 36:205-213 (Pubitemid 41136292)
42. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104:3865-3871 (Pubitemid 39620131)
43. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M (2002) Reduced-intensity conditioning followed by all grafting of hematopoietic cells can produce clinical and molecular remission in patients with poor-risk hematologic malignancies. Blood 99:75-82
44. Bierman PJ, Sweetenham JW, Jr L, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, vose JM, Horowitz M, Goldstone A (2003) Syngenic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation J Clin Oncol 32:3744-3753 (Pubitemid 46606228)
45. Robinson SP, Sureda A, Canals C, Russel N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting oucome. Hematologica 94:230-238
46. Rezvani AR, Norasetthada L, Gooley T, Sorror M, Bouvier ME, Sahebi F, Agura E, Chauncey T, Maziarz RT, Maris M, Shizuru J, Bruno B, Bredeson C, Lange T, Yeager A, Sandmaier BM, Storb RF, Maloney DG (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicenter experience. Br J Hematol 143:395-403
47. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-agha I, Mohty M, Robin M, Tabrizi R, Clement L, Bilger K, Larosa F, Contentin N, Huyn A, Francos S, Bulabois CE, Ceballos P, Bourrhis JH, Buzyn A, Cornilllon J, Guillerm G, de Revel T, Bay JO, Guilhot F, Milpied N (2010) Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 16(1):78-85